Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)

BACKGROUND: Lanreotide autogel is a somatostatin analog (SSA) approved for the treatment of acromegaly in 73 countries worldwide; however, it is not yet approved in China. The aim of this study was to evaluate the efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged rel...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Zhenmei, Lei, Ting, Duan, Lian, Hu, Pei, Gou, Zhongping, Zhang, Lihui, Durand-Gasselin, Lucie, Wang, Nan, Wang, Yan, Gu, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199333/
https://www.ncbi.nlm.nih.gov/pubmed/32366244
http://dx.doi.org/10.1186/s12902-020-0524-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199333/
https://www.ncbi.nlm.nih.gov/pubmed/32366244
http://dx.doi.org/10.1186/s12902-020-0524-7

Ejemplares similares